External validation of the risk assessment model of the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) for medical patients in a tertiary health system - PubMed (original) (raw)
Multicenter Study
External validation of the risk assessment model of the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) for medical patients in a tertiary health system
David Rosenberg et al. J Am Heart Assoc. 2014.
Abstract
Background: Hospitalized medical patients are at risk for venous thromboembolism (VTE). Universal application of pharmacological thromboprophylaxis has the potential to place a large number of patients at increased bleeding risk. In this study, we aimed to externally validate the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) VTE risk assessment model in a hospitalized general medical population.
Methods and results: We identified medical discharges that met the IMPROVE protocol. Cases were defined as hospital-acquired VTE and confirmed by diagnostic study within 90 days of index hospitalization; matched controls were also identified. Risk factors for VTE were based on the IMPROVE risk assessment model (aged >60 years, prior VTE, intensive care unit or coronary care unit stay, lower limb paralysis, immobility, known thrombophilia, and cancer) and were measured and assessed. A total of 19 217 patients met the inclusion criteria. The overall VTE event rate was 0.7%. The IMPROVE risk assessment model identified 2 groups of the cohort by VTE incidence rate: The low-risk group had a VTE event rate of 0.42 (95% CI 0.31 to 0.53), corresponding to a score of 0 to 2, and the at-risk group had a VTE event rate of 1.29 (95% CI 1.01 to 1.57), corresponding to a score of ≥3. Low-risk status for VTE encompassed 68% of the patient cohort. The area under the receiver operating characteristic curve was 0.702, which was in line with the derivation cohort findings.
Conclusions: The IMPROVE VTE risk assessment model validation cohort revealed good discrimination and calibration for both the overall VTE risk model and the identification of low-risk and at-risk medical patient groups, using a risk score of ≥3. More than two thirds of the entire cohort had a score ≤2.
Keywords: clinical prediction rules; hospitalized medical patients; risk assessment models; thromboprophylaxis; venous thromboembolism.
© 2014 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell.
Figures
Figure 1.
Definition study population. DRG indicates diagnosis‐related group; ICD‐9, International Classification of Diseases, 9th revision; INR, international normalized ratio; LIJMC, Long Island Jewish Medical Center; LOS, length of stay; NSUH, North Shore University Hospital; VTE, venous thromboembolism.
Figure 2.
Receiver operating characteristic curve for the validation cohort was 0.70.
Similar articles
- External validation of a risk assessment model for venous thromboembolism in the hospitalised acutely-ill medical patient (VTE-VALOURR).
Mahan CE, Liu Y, Turpie AG, Vu JT, Heddle N, Cook RJ, Dairkee U, Spyropoulos AC. Mahan CE, et al. Thromb Haemost. 2014 Oct;112(4):692-9. doi: 10.1160/TH14-03-0239. Epub 2014 Jul 3. Thromb Haemost. 2014. PMID: 24990708 - Venous Thrombosis Risk after Cast Immobilization of the Lower Extremity: Derivation and Validation of a Clinical Prediction Score, L-TRiP(cast), in Three Population-Based Case-Control Studies.
Nemeth B, van Adrichem RA, van Hylckama Vlieg A, Bucciarelli P, Martinelli I, Baglin T, Rosendaal FR, le Cessie S, Cannegieter SC. Nemeth B, et al. PLoS Med. 2015 Nov 10;12(11):e1001899; discussion e1001899. doi: 10.1371/journal.pmed.1001899. eCollection 2015 Nov. PLoS Med. 2015. PMID: 26554832 Free PMC article. - Derivation and validation of a simple model to identify venous thromboembolism risk in medical patients.
Woller SC, Stevens SM, Jones JP, Lloyd JF, Evans RS, Aston VT, Elliott CG. Woller SC, et al. Am J Med. 2011 Oct;124(10):947-954.e2. doi: 10.1016/j.amjmed.2011.06.004. Am J Med. 2011. PMID: 21962315 - Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients.
Cohen AT, Alikhan R, Arcelus JI, Bergmann JF, Haas S, Merli GJ, Spyropoulos AC, Tapson VF, Turpie AG. Cohen AT, et al. Thromb Haemost. 2005 Oct;94(4):750-9. Thromb Haemost. 2005. PMID: 16270626 Review. - The use of weighted and scored risk assessment models for venous thromboembolism.
Spyropoulos AC, McGinn T, Khorana AA. Spyropoulos AC, et al. Thromb Haemost. 2012 Dec;108(6):1072-6. doi: 10.1160/TH12-07-0508. Epub 2012 Nov 8. Thromb Haemost. 2012. PMID: 23138506 Review.
Cited by
- Pulmonary Embolism: A Complication of COVID-19 or Drug Abuse?
Gaba M, Kumar N, Pandey A, Reddy BVVK, Dewan A. Gaba M, et al. Cureus. 2024 Sep 20;16(9):e69821. doi: 10.7759/cureus.69821. eCollection 2024 Sep. Cureus. 2024. PMID: 39435195 Free PMC article. - Upper Extremity Deep Vein Thrombosis: Incidence, Risk Factors, and Effectiveness of Chemoprophylaxis.
Olt CK, Hu B, Rothberg MB. Olt CK, et al. South Med J. 2024 Sep;117(9):534-538. doi: 10.14423/SMJ.0000000000001728. South Med J. 2024. PMID: 39227045 - Low incidence of deep vein thrombosis in critically ill medical patients in Thais: a prospective study.
Arunothai S, Sutherasan Y, Panpikoon T, Theerawit P, Angchaisuksiri P, Boonyawat K. Arunothai S, et al. Res Pract Thromb Haemost. 2024 Jul 22;8(5):102522. doi: 10.1016/j.rpth.2024.102522. eCollection 2024 Jul. Res Pract Thromb Haemost. 2024. PMID: 39221448 Free PMC article. - Validation of the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) risk scores for venous thromboembolism and bleeding in an independent population.
Wilkinson KS, Sparks AD, Gergi M, Repp AB, Al-Samkari H, Thomas R, Roetker NS, Zakai NA. Wilkinson KS, et al. Res Pract Thromb Haemost. 2024 May 15;8(4):102441. doi: 10.1016/j.rpth.2024.102441. eCollection 2024 May. Res Pract Thromb Haemost. 2024. PMID: 38953050 Free PMC article. - Universal EHRs Clinical Decision Support for Thromboprophylaxis in Medical Inpatients: A Cluster Randomized Trial.
Spyropoulos AC, Goldin M, Koulas I, Solomon J, Qiu M, Ngu S, Smith K, Leung T, Ochani K, Malik F, Cohen SL, Giannis D, Khan S, McGinn T. Spyropoulos AC, et al. JACC Adv. 2023 Sep 13;2(8):100597. doi: 10.1016/j.jacadv.2023.100597. eCollection 2023 Oct. JACC Adv. 2023. PMID: 38938337 Free PMC article.
References
- Anderson FA, Zayaruzny M, Heit JA, Fidan D, Cohen AT. Estimated annual numbers of US acute‐care hospital patients at risk for venous thromboembolism. Am J Hematol. 2007; 82:777-782. - PubMed
- Belch JJ, Lowe GD, Ward AG, Forbes CD, Prentice CR. Prevention of deep vein thrombosis in medical patients by low‐dose heparin. Scott Med J. 1981; 26:115-117. - PubMed
- Nielsen HK, Bechgaard P, Nielsen PF, Geday E, Husted SE. Fatal pulmonary embolism in a medical department. Clinic‐pathological correlations and therapeutic deliberations. Ugeskr Laeger. 1981; 143:1956-1960. - PubMed
- Flanders SA, Greene MT, Grant P, Kaatz S, Paje D, Lee B, Barron J, Chopra V, Share D, Bernstein SJ. Hospital performance for pharmacologic venous thromboembolism prophylaxis and rate of venous thromboembolism: a cohort study. JAMA Intern Med. 2014; 174:1577-1584. - PubMed
- Qaseem A, Chou R, Humphrey LL, Starkey M, Shekelle PPhysicians CGCotACo. Venous thromboembolism prophylaxis in hospitalized patients: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2011; 155:625-632. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous